

(ii) a drug that is dissolved in the emulsion, wherein more than 50% of the drug on a weight basis is dissolved in the oil phase of the emulsion, wherein the oil phase comprises a hydroxylated oil, and the drug is for systemic delivery and is selected from the group consisting of an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence, and a non-steroidal anti-inflammatory drug, but wherein the drug is not a cannabinoid.

*B1*  
*Cancelled*

2. (Twice amended) A composition adapted for nasal administration comprising  
(i) an oil-in-water emulsion and  
(ii) a drug that is dissolved in the emulsion, wherein more than 50% of the drug on a weight basis is dissolved in the oil phase of the emulsion, wherein the oil phase comprises a hydroxylated oil, and the drug is for systemic delivery and is selected from the group consisting of an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence-and-a-non-steroidal anti-inflammatory drug, but wherein the drug is not a cannabinoid, for use in medicine.

*B2*

9. (Amended) A composition according to claim 1, wherein more than 75 % of the drug is dissolved in the oil phase on a weight basis.

Please add claims 15, 16, and 17 as follows.

15. (New) A composition according to claim 2, wherein more than 75% of the drug is dissolved in the oil phase on a weight basis.

*B3*

16. (New) The pharmaceutical composition of claim 1, wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of ibuprofen, flurbiprofen, diclofenac, indomethacin, piroxicam, ketoprofen, etodolac, diflusinal, meloxicam, aceclofenac, fenoprofen, naproxen, tiaprofenic acid, and tolmetin.

17. (New) The composition of claim 2, wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of ibuprofen, flurbiprofen, diclofenac,